skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Namodenoson (Code C79826)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Namodenoson

Definition: An orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist with potential antineoplastic activity. Namodenoson selectively binds to and activates the cell surface-expressed A3AR, deregulating Wnt and NF-kB signal transduction pathways downstream, which may result in apoptosis of A3AR-expressing tumor cells. A3AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of various solid tumor cell types, including hepatocellular carcinoma (HCC) cells, and plays an important role in cellular proliferation.

Label: Namodenoson

NCI Thesaurus Code: C79826 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0289969  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
A3AdR Agonist CF102
Adenosine Receptor A3 Agonist CF102
beta-D-Ribofuranuronamide, 1-(2-Chloro-6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-1-deoxy-N-methyl-

External Source Codes: 
CAS Registry Number 163042-96-4 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 626663
PDQ Open Trial Search ID 626663 (check for NCI PDQ open clinical trial info)
UMLS CUI C0289969

Other Properties:
     Name Value (qualifiers indented underneath)
code C79826
Legacy_Concept_Name Adenosine_A3_Receptor_Agonist_CF102
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom